Company Profile

Purple Biotech Ltd. (NASDAQ: PPBT)
5:30 PM UTC, 07/03/24
Last: $0.36 Change: -0.01 %Change: -1.95% Volume: 104,573
Detailed Quote
Open: $ 0.37   Volume: 104,573
High: $ 0.37   Yield(%) 0.00
Low: $ 0.36   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 10.24M
EPS ($) -0.82   Shares Out: 27.66M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -40.36
% Price Change (last 13 weeks): -45.18
% Price Change (last 26 weeks): -52.01
% Price Change (last 52 weeks): -73.40
% Price Change (year to date): -52.56
Management Effectiveness
Return on Equity (%): -49.02
Return on Assets (%): -40.19
Return on Invested Capital (%): -45.85
Profitability
Gross Profit Margin (%): n/a
Net Profit Margin (%): n/a
Operating Profit Margin (%): 0.00
Price & Volume
50-day Moving Average: $0.56
200-day Moving Average: $0.81
Avg. Daily Vol. (last 50 days): 370,709
Avg. Daily Vol. (last 200 days): 171,382
52-wk high: $1.80
52-wk low: $0.30
Bid: $0.34
Ask: $0.40
Company Information
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
Purple Biotech Ltd.
Science Park 4 Oppenheimer Street
Rehovot TA 7670104

Phone: 972.3.933.3121
Fax: n/a
http://ww.purple-biotech.com
Per Share Data
Earnings (1year) ($): -0.82
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 1.39
Cash Flow ($): -0.80
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): n/a
Price/Book (x): 0.56
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 2.20
Current Ratio (x): 2.20
LT Debt/Equity (x): 0.48
Total Debt/Equity (x): 1.03



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.